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Abstract
BACKGROUND—Maternal folate intake and related biomarkers have been inconsistently 
associated with a risk of oral clefts.
METHODS—Maternal concentrations of plasma folate (PF) and erythrocyte folate (EF), plasma 
pyridoxal-5′-phosphate (PLP; active vitamin B6) and total plasma homocysteine (tHcy) were 
measured in a Utah study with 347 cases and 469 controls.
RESULTS—Risk of all clefts combined, including cleft lip with or without cleft palate (CL/P) 
and cleft palate only (CP), was 65% lower in the highest versus lowest PF quartile (odds ratio 
[OR], 0.35; 95% confidence interval [CI], 0.23–0.53; p-trend < 0.001). Results remained 
significant in the subgroups with isolated CL/P and CP (p-trend < 0.001 in each). EF results were 
similar. In the highest versus lowest PLP quartile, risk of CP with other malformations was lower 
(OR, 0.25; 95% CI, 0.07–0.95); however, no other associations were significant for PLP or tHcy. 
Differences in mean bio-marker levels between cases and controls widened with an increasing 
interval between delivery and maternal blood collection. Decreased cleft risk with increasing 
quartiles of PF, EF, and PLP and decreasing tHcy was more apparent in mothers with a longer 
versus shorter interval between the index child delivery and blood collection.
CONCLUSION—Low maternal blood folate concentration was associated with an increased risk 
of clefts, and the differences in mean case and control PF, EF, PLP, and tHcy concentrations 
widened over time. Additional mechanistic studies are warranted to elucidate whether an acquired 
or inherited disorder of folate metabolism plays a role in the etiology of clefts.
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INTRODUCTION
Oral clefts are among the most common birth defects; they comprise a broad spectrum of 
anomalies including cleft lip (CL), cleft palate (CP), or both, in either isolation or 
association with other malformations. Common groupings of clefts for surveillance and 
etiologic studies include CL, with or without cleft palate (CL/P) and CP. Considerable 
variation exists in the occurrence of clefts by social class, by geographic area, and between 
resident and migrant groups of the same ethnicity, indicating an environmental component 
to the causes (Mossey et al., 2009). Among the U.S. states with statewide birth defects 
registries with active surveillance, Utah has the highest birth prevalence of clefts and the 
rates are generally higher in western states compared to eastern states (Gebreab et al., 2008).
Maternal deficiency of a wide variety of nutrients has long been related to the risk for clefts 
in experimental animals (Munger, 2002). In meta-analyses of human observational studies, 
maternal multivitamin use was associated with a reduced risk of clefts (Badovinac et al., 
2007; Johnson and Little, 2008), although an analysis of data from the U.S. National Birth 
Defects Prevention Study (a case-control study) indicated no association (Shaw et al., 2006).
The well-established relationship between periconceptional folic acid supplementation and 
reduced risk of neural tube defects (NTDs; MRC Vitamin Study Research Group, 1991) 
suggests that a similar relationship may exist for clefts, because certain structures of the 
craniofacial region are derived from cephalic neural crest cells. Therefore, it is plausible that 
these birth defects share common developmental origins and risk factors for abnormal 
development (Been and Lieuw Kie Song, 1978; Lammer et al., 1985). Epidemiologic data, 
however, reveal important differences between NTDs and clefts in their patterns of 
geographic occurrence and in changes in birth prevalence over time; therefore, the causes of 
clefts may be different from NTDs. In China, NTD rates are higher in the north than the 
south, whereas clefts do not follow this pattern. (Berry et al., 1999; Dai et al., 2004) In most 
countries where sharp declines in the NTD rates were observed over the past decades, cleft 
rates have been relatively stable (International Clearinghouse for Birth Defects Surveillance 
and Research, 2008). Studies of dietary folate intake (Wilcox et al., 2007; Johnson and 
Little, 2008; Little et al., 2008a;) and of folate-related genes (Mossey et al., 2009) have 
resulted in inconsistent associations with the risk of clefts. If folate nutritional status is 
related to the etiology of clefts, this association and its modifying factors may differ from 
that of NTDs.
Folate plays important roles in one-carbon transfer reactions, including amino acid 
metabolism, formate oxidation, and purine and thymidylate biosynthesis, which are building 
blocks of DNA and RNA. Therefore, adequate status of folate is important for growth and 
development early in life (Tamura and Picciano, 2006). Folate-related biomarkers involved 
in one-carbon metabolism may be useful in studies of the association between maternal 
folate nutrition and clefts. However, findings of studies associating these biomarkers with 
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the risk of clefts have been inconsistent. In the Netherlands, case mothers of children with 
clefts had higher serum and erythrocyte folate concentrations, but lower plasma 
pyridoxal-5′-phosphate (PLP) and higher total homocysteine (tHcy) compared with control 
mothers of children without malformations (Wong et al., 1999). In a subsequent Netherlands 
study, case mothers with low vitamin B12 and B6 levels had an increased risk of clefts in 
their children, whereas folate concentrations were not significantly different between case 
and control mothers (van Rooij et al., 2003). In a U.K.-based case-control study, higher 
serum and erythrocyte folate concentrations were associated with decreased risk of CLP but 
an increased risk of CP (Little et al., 2008b). In the Philippines, low plasma PLP 
concentrations were common and associated with increased cleft risk, although plasma and 
erythrocyte folate concentrations were inconsistently associated with cleft risk. We suggest 
that these associations are modified by inadequate vitamin B6 status in the population 
(Munger et al., 2004; Tamura et al., 2007).
Our objective was to determine whether biomarkers related to one-carbon metabolism, 
including concentrations of plasma and erythrocyte folate, plasma PLP, and plasma tHcy in 
mothers, were associated with risk of clefts in their children.
MATERIALS AND METHODS
Subjects and Samples
A state-wide case-control study of clefts was conducted in Utah during 2000 to 2005 in 
collaboration with the Utah Birth Defects Network (UBDN), a state-wide birth defects 
registry operated by the Utah Department of Health (UDOH). All study procedures were 
reviewed and approved by the institutional review boards of Utah State University (USU), 
the University of Utah, the UDOH, and the University of Alabama at Birmingham. Eligible 
case mothers included Utah residents with a live-born or stillborn child with a cleft between 
January 1, 1995, and June 30, 2004. Clefts and associated birth defects were classified after 
a review of all available medical records by the UBDN, including a medical geneticist 
(J.C.C.). Cleft cases with known genetic syndromes or chromosomal abnormalities were 
excluded from the present analyses. Control mothers were randomly selected using Utah 
birth certificate files that were frequency matched to cases by month and year of delivery 
and sex of the child; they were recruited at a rate projected to result in a 1:1 ratio of 
completed interviews with cases. The UDOH authorized the limited use of UBDN data to 
recruit case mothers of children with clefts and the use of Utah birth certificate files to 
recruit control mothers of children without birth defects. The UBDN staff members 
attempted to contact potential case and control mothers by mail to obtain consent for release 
of their names to USU investigators. Address updates were sought using available internet 
services. If no mailing address was available, attempts were made to locate the mothers in 
person by field tracing that included visits to the last known home address and inquiries with 
neighbors.
Interviews with mothers were conducted primarily by telephone; however, personal 
interviews were completed if no telephone was available. The interview included questions 
on demographic characteristics of the biologic parents, a reproductive health and pregnancy 
history, supplement use, medications, medical conditions, and smoking and alcohol use. 
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Each mother received an individualized, color-coded pregnancy calendar that was generated 
based on the date of delivery of her index child and the self-reported gestational length. This 
visual aid was intended to assist mothers in recalling activities and timing of events during 
various periods referred to. Color-coding of the calendars indicated the reference periods 
including the 3-month period before the estimated date of conception and three trimesters. 
Interview materials were translated into Spanish, and mothers speaking Spanish only were 
contacted by a bilingual interviewer.
Maternal blood samples were obtained in evacuated tubes containing EDTA (BD 
Vacutainer; Preanalytical Solutions, Franklin Lake, NJ) from mothers ≥12 months after the 
end of their last pregnancy to avoid artifacts of the effects of pregnancy and lactation 
(Murphy et al., 2002). Blood samples were kept on ice and processed within 2 hours of 
collection. Aliquots of whole blood for folate assays were mixed with a 1% ascorbic acid 
solution. Samples were shipped on dry ice to Birmingham, Alabama, and were kept at 
−80°C until analysis.
Laboratory Analyses
Plasma and erythrocyte folate concentrations were determined by microbiologic assay using 
Lactobacillus rhamnosus as described previously (Tamura, 1990). Erythrocyte folate was 
assayed after whole blood lysates were incubated for 60 minutes at 37°C (pH 4.2) to 
hydrolyze polyglutamyl folates using endogenous plasma folate conjugase. The calculation 
of erythrocyte folate was done by the following formula: erythrocyte folate concentration = 
[Whole blood folate concentration − Plasma folate concentration × (1 − Hematocrit)] ÷ 
Hematocrit. Plasma tHcy assay was performed by a high-pressure liquid chromatography-
fluorescent method (Tamura et al., 1996). Plasma PLP concentrations were measured by the 
tyrosine-apodecarboxylase method using [3H]-tyrosine as a substrate (Alpco Diagnostics, 
Windham, NH).
Data Management and Statistical Methods
An integrated data management system allowed tracking of recruitment progress, data, and 
blood collection across study sites. Quality-assurance procedures consisted of two 
independent reviews of interview forms and coding. Data entry forms were created in SPSS 
Data Builder (SPSS, Inc., Chicago, IL), and two independent data entries were made with 
the second data entry technician responsible for reconciliation. SPSS and SAS (SAS 
Institute, Inc., Cary, NC) data files were created for data analyses.
The means of continuous variables of case and control mothers were compared and 
evaluated with the t test after the values were log-transformed, if they were not normally 
distributed. The chi-square test was used to test for differences in the distribution of 
categorical variables between case and control mothers. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated to estimate the relative risk of clefts across 
quartiles of plasma and erythrocyte folate, plasma PLP, and plasma tHcy. Quartiles of each 
variable were defined using data from case and control mothers combined, and the reference 
quartile was the lowest. Logistic-regression analyses were used to estimate ORs while 
adjusting for differences in covariates, including maternal age, education level of mother, 
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alcohol use, smoking, multivitamin use, and the time interval between delivery of the index 
child and collection of the maternal blood sample. Tests for linear trends of ORs across 
quartiles of variables were performed using the median level within each quartile. 
Differences in biomarker means between groups defined by the interval between delivery of 
the index child and collection of the maternal blood sample (12–36, >36–60, ≥60 months) 
were evaluated with one-way ANOVA. Analyses of cleft risk by biomarker quartiles were 
also stratified by these intervals.
RESULTS
We identified 893 eligible case mothers who delivered a child with a cleft. Among these 
case mothers, 14.9% refused to allow the UBDN to release their name to USU for 
recruitment, and 11.2% could not be located; one case mother was deceased, two spoke 
neither English nor Spanish, and four had other reasons for not releasing their names. 
Among the control mothers, the rate of initial refusal for recruitment was higher (28.3%), as 
was the percentage that could not be located (14.6%); two control mothers were deceased; 
four spoke neither English nor Spanish; nine were excluded because they had delivered a 
child with a cleft; and 17 were excluded for other reasons. The names of 653 case mothers 
(73.1%) and 782 control mothers (54.8%) were released by the UBDN for recruitment. 
Recruitment of mothers involved direct mail and telephone contact with case and control 
mothers, with the result being that among the name-released mothers 86.8% of the cases and 
84.8% of the controls completed interviews with USU staff members. Of the case mothers, 
8.1% refused to be interviewed, and 5.1% could not be interviewed for other reasons. Of the 
control mothers, 12.7% refused to be interviewed, and 2.5 could not be interviewed for other 
reasons. The overall results of the two stages of recruitment were that interviews were 
completed with 565 (63.4%) of the identified case mothers and 660 (46.4%) selected 
control-mothers. Blood samples for laboratory analyses were collected from 404 (71.5%) of 
the interviewed case mothers and 469 (71.1%) of the interviewed control mothers. Cases 
with known genetic syndromes or chromosomal abnormalities (n = 57) were excluded from 
the data analyses.
Cleft subgroups in the analyses included isolated CL/P (CL/P-I) and isolated CP (CP-I) and 
CL/P and CP with multiple birth defects (CL/P-M and CP-M). The characteristics of 
mothers in each of the four case subgroups and control mothers appear in Table 1. The sex 
distribution of control and all case children combined was similar because of the frequency 
matching by sex. Among the cases, the sex distribution by cleft subtype was similar to 
findings elsewhere (Mossey et al., 2009), with a male predominance for CL/P-I and CL/P-M 
cases, an equal distribution for CP-I, and a female predominance for CP-M cases. The 
ethnicity of mothers reflected the Utah population, with 91% of case mothers and 89% of 
control mothers self-identifying as Caucasian. The mean maternal and paternal ages at the 
delivery of the index child were similar between the controls and case subgroups as were the 
means of maternal weight, height, and body mass index. Multivitamin use was common 
(>65% by the second month of pregnancy), but not significantly different between case and 
control mothers. Parity at the time of the index delivery and at the time of blood collection 
was not different between case and control mothers. The interval between the index delivery 
and maternal blood collection was longer for controls than cases: 4.3 years for controls (SD 
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= 2.3); 3.8 (SD = 2.2) for CL/P-I; 3.4 (SD = 2.2) for CP-I; 3.5 (SD = 2.1) for CL/P-M; 3.6 
(SD = 2.4) for CP-M.
Mean plasma and erythrocyte folate and plasma PLP concentrations were lower in the case 
mothers than in control mothers, whereas mean plasma tHcy was similar between the two 
groups. The risk of having a child with any cleft (all subgroups combined) declined in a 
dose-response manner with increasing quartile of plasma folate (quartile 1 is reference, 
quartile 2 [OR, 0.83; 95% CI, 0.56–1.25], quartile 3 [OR, 0.59; CI, 0.39–0.89], quartile 4 
[OR, 0.35; CI, 0.23–0.53]; p-trend < 0.001). This pattern was observed for the subgroups of 
CL/P-I and CP-I, and it was similar for CL/P-M and CP-M, although the results in these 
later two groups were not significant, perhaps owing to small sample sizes. The results for 
erythrocyte folate were similar but less striking. The risk of having a child with any cleft 
declined with increasing quartile of erythrocyte folate (quartile 1 is reference, quartile 2 
[OR, 0.82; CI, 0.55–1.23], quartile 3 [OR, 0.56; CI, 0.38–0.85], quartile 4 [OR, 0.64; CI, 
0.42–0.97]; p-trend = 0.01).
In the highest versus lowest PLP quartile, risk of CP-M was 75% less (OR, 0.25; 95% CI, 
0.07–0.95), whereas there was not a dose-response gradient across quartiles (p-trend = 0.92) 
as in the plasma folate findings. There was a tendency of a reduction in risk of CL/P-I, CP-I, 
and CL/P-M in the highest quartile compared with the lowest quartile of PLP; however, 
these results did not achieve significance (Table 2). The means of plasma tHcy of all groups 
were low as a result of the era of folic acid fortification (Pfeiffer et al., 2007). Plasma tHcy 
was not significantly associated with cleft risk when either all clefts combined or individual 
cleft subgroups were evaluated (Table 2).
When mean plasma folate concentrations of case and control mothers were compared by 
intervals between index delivery and maternal blood collection (12–36, 36–60, and ≥60 
months), an unexpected pattern emerged: a widening difference between the cases and 
controls with increasing time since the index delivery. This analysis combined all cases of 
clefts, because the analyses across additional strata exhausted the sample size of individual 
cleft subgroups. The means of plasma folate for controls versus all cleft cases were 64 
versus 59 nmol/L for the 12- to 36-month interval (p = 0.09), 65 versus 45 for the >36- to 
60-month interval (p < 0.001), and 65 versus 48 for the interval ≥60 months (p < 0.001; Fig. 
1). As shown in Table 3, ANOVA models contrasting the plasma folate means of case and 
control mothers separately across the intervals indicated a significant decline of means of the 
case mothers after the 12- to 36-month interval (p < 0.001), whereas the means of control 
mothers were not significantly different across the intervals (p = 0.98). Similar results were 
observed for erythrocyte folate with a significant decline for case mothers (p = 0.01) and no 
significant differences for control-mothers over the interval (p = 0.13). PLP means declined 
over the periods for case mothers, although the differences were not significant. Means of 
tHcy demonstrated an inverse pattern with a significant stepwise increase with increasing 
time for case mothers (p = 0.01) and a nonsignificant increase in means for control mothers 
(p = 0.21).
The modifying effect of the interval between index delivery and blood collection on the risk 
of clefts in association with laboratory indices was further evaluated in logistic-regression 
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analyses (Table 4). In general, stronger associations emerged between increasing plasma 
folate quartiles and reduced cleft risk, with longer time elapsed between the index delivery 
and blood collection. The association was not significant for the 12- to 36-month interval, 
although a significant dose-response manner of protection was seen in the >36- to 60-month 
interval (p-trend < 0.001) and the >60-month interval (p-trend < 0.001). A similar pattern 
was observed for erythrocyte folate with no significant association in the 12- to 36-month 
interval (p-trend = 0.97) and a significant protective association in the 36- to 60-month 
interval (p-trend = 0.01) and the >60-month interval (p-trend = 0.004). The PLP data, 
stratified by the same intervals, were suggestive of a protective association in the longer 
interval, although this was not significant. An association between higher levels of tHcy and 
higher cleft risk was apparent in the >60-month interval (quartile 4 vs quartile 1: OR, 2.23; 
95% CI, 1.01–4.91; p-trend 0.056), and this association was not apparent in the two earlier 
intervals.
DISCUSSION
In a population-based, case-control study in Utah, certain maternal biomarkers related to 
folate metabolism were associated with cleft risk. Among our findings, the observation that 
higher plasma folate concentrations were associated with a reduced cleft risk in a dose-
response manner may be the most notable. Findings were similar for erythrocyte folate. 
Higher PLP concentrations were associated with reduced cleft risk, with statistical 
significance only in the subgroup with CP-M. Plasma tHcy concentration was not 
significantly associated with cleft risk in the overall analyses.
The observation of significant case-control differences in blood folate concentrations is 
unexpected in the era after folic acid fortification of enriched cereal-grain products was 
allowed to be practiced by food manufacturers starting March 1996 and became mandatory 
in January 1998 (U.S. Food and Drug Administration, 1996). This fortification program 
made blood folate concentrations markedly higher and tHcy lower than before the mandate 
(Pfeiffer et al., 2007). All of the mothers in our study provided blood samples 2 years or 
more after the mandatory folic acid fortification. Further, multivitamins were used by more 
than 65% of case and control mothers by the second month of their index pregnancy; this in 
combination with the high folic acid intake from fortified foods suggests that the majority of 
our study participants in general had a more than adequate folate intake at the time of their 
index pregnancy and the later blood collection. Therefore, our finding of significantly lower 
plasma and erythrocyte folate concentrations in case mothers than in control mothers is 
puzzling and requires careful scrutiny. Although no clear explanation can be offered, this 
finding may be due to endogenously altered, folate-dependent, one-carbon metabolism 
secondary to unidentified, inherited or acquired conditions rather than the result of low 
folate intake among the case mothers.
The case-control study design was used in this study because the alternative observational 
study design (i.e., a prospective cohort study) would have been prohibitively expensive. The 
use of biomarkers based on laboratory assays in retrospective studies of pregnancy outcomes 
rests on the assumption that the determinants—nutritional intake and acquired and 
genetically inherited determinants of metabolic function—are relatively constant over a 
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period of years after the index pregnancy. Longitudinal studies lend support to the view that 
patterns of dietary intake, physical activity, and other behaviors of mothers tend to return to 
the preconception trajectory after the delivery of a child. Maternal erythrocyte folate levels 
determined 1 year after delivery in a study in London were correlated with values 
determined early in pregnancy (Leck et al., 1983). In a study of lifestyle habits from 
pregnancy through the postpartum period, few women departed from prepregnancy 
trajectories in three categories in the postpartum period, including weight orientation, diet, 
and physical activity (Devine et al., 2000). In a prospective study to evaluate the association 
between preconception and early pregnancy exposures and pregnancy outcomes, the nutrient 
intakes of women were assessed with a food-frequency questionnaire 3 to 7 years after their 
index pregnancies. These questionnaires were compared to values determined with the same 
method during their index pregnancies, and the agreement was comparable to that found in 
studies of nonpregnant adults over the same time interval. In addition, Bunin et al. (2001) 
reported that the recall was similar among women with a shorter interval between 
assessments (<4.5 years) compared to those with a longer interval (≥4.5 years).
The biomarker assays used in this study may provide measures of the collective effects of 
variation in dietary and supplemental intake of nutrients combined with a variance in 
metabolism that results from interactions with other nutrients, environmental factors, and 
genes. This complex chain of events from nutrient consumption, through absorption, 
storage, utilization, and excretion, also means that observed case-control differences in 
measured biomarker levels may have many possible explanations other than variance in 
nutrient intake (Willett, 1990). The use of biomarkers also provides objective data that may 
reduce the recall bias that can distort recall between case and control mothers in 
retrospective studies; it also allows for the simultaneous examination of multiple nutrients.
An unexpected finding was that stronger associations among increasing quartiles of plasma 
and erythrocyte folate and reduced cleft risk, as well as between increasing plasma tHcy 
quartiles and increased cleft risk, emerged in stratified analyses of longer versus shorter 
intervals between delivery of the index child and maternal blood collection. This finding 
appeared to be the result of relatively stable mean concentrations for control mothers and 
significant declines in mean concentrations for case mothers over these intervals. The 
emergence of stronger associations between biomarkers of one-carbon metabolism with 
increasing time since the delivery of the index child suggests the possibility that a disorder 
of folate-dependent one-carbon metabolism may play a role in the etiology of clefts, and that 
this disorder becomes more apparent with the passage of time after the affected pregnancy. 
This conclusion, however, is based on the interpretation of cross-sectional data, and future 
longitudinal studies will be necessary to verify this observation.
Although the findings of the Utah study could be generalized to other areas in the developed 
world, they may not be directly applicable to nutritionally impoverished populations in 
developing countries where no fortification program is practiced, and few prenatal vitamins 
are available. For example, in our studies in the Philippines where the same methods for 
sample collection and laboratory analyses were used, we found that the association between 
blood folate concentration and cleft risk was inconsistent, and this association appeared to 
be modified by the level of maternal vitamin B6 status (Munger et al., 2004). In the 
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Philippines, inadequate vitamin B6 status was common in women of reproductive age and 
was independently associated with increased cleft risk (Tamura et al., 2007). In the Utah 
study, maternal vitamin B6 status, as judged by plasma PLP, appeared to be less strongly 
associated with cleft risk compared with plasma and erythrocyte folate concentrations. We 
reported widespread inadequate maternal plasma zinc levels in the Philippines that were 
strongly associated with cleft risk (Tamura et al., 2005). In contrast, we found generally 
adequate maternal zinc status and no significant association between zinc status and cleft 
risk in Utah (Munger et al., 2009).
Strengths of the current study include the statewide ascertainment of case mothers using a 
birth defects registry with multiple sources of case ascertainment and the random selection 
of control mothers using all Utah births without clefts from the same time period as the 
sampling frame. The collection and rapid processing of maternal blood specimens and 
assays of biomarkers added an objective aspect to the study beyond the collection of 
interview data alone. An additional strength of the study was the detailed review of each 
case by a clinical geneticist. This procedure is standard for the Utah Birth Defects Network 
and can generate the clinical classifications by type of cleft, pattern of other birth defects, 
chromosomal abnormalities, and known genetic syndromes. Whereas cleft cases with 
chromosomal abnormalities or known genetic syndromes were excluded from the data 
analyses, it is possible that abnormalities in one-carbon metabolism may be involved in 
those cases as well. The participation rates can be considered relatively high and were due to 
active recruitment through multiple methods including mail, telephone, and face-to-face 
contacts.
A potential limitation of the design of retrospective case-control studies is recall bias; 
however, this would not have affected the biomarker levels measured in the maternal blood 
specimens. A potential bias that may have affected observed biomarker values or other 
covariates is the differential response rate between cases and controls. More case mothers 
than controls (73.1% vs. 54.8%) responded to the request by the Utah Department of Health 
to release their names to study investigators for recruitment; however, no personal 
information or bio-marker data were available from nonrespondents to allow the evaluation 
of potential response bias. Once names were released for recruitment, a similar percentage 
of case and control mothers completed the interview (86.8% vs. 84.8%); of these, a similar 
percentage provided a blood specimen (71.5% vs. 71.1%). A prospective approach to data 
collection with enrollment of mothers before pregnancy would be ideal; however, it would 
have been extremely difficult because of the large sample size required and its high cost. 
Additional limitations were the small sample size for clefts with multiple birth defects and 
the exclusion of clefts with known genetic syndromes and chromosomal abnormalities 
because of the heterogeneity of these cases and their small numbers. It is possible that the 
biomarker associations observed with the isolated clefts are relevant for these subgroups of 
clefts, although larger studies will be necessary. Although some may view a biomarker study 
conducted years after the affected pregnancy as a weakness, we have cited evidence to 
support the view that nutrient intakes and related metabolic factors are relatively stable. In 
addition, this study design has revealed a decline in folate status of case mothers relative to 
control mothers over time, suggesting that biomarker studies after a reasonable time from 
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delivery can unmask biochemical variations in nutritional studies that would be difficult to 
identify by dietary recall studies or blood sampling immediately after delivery.
The Utah study of maternal biomarkers of folate-dependent one-carbon metabolism provides 
evidence of the involvement of this metabolic pathway in the risk of clefts. The currently 
high rates of clefts in Utah and other western states (Gebreab et al., 2008) remain 
unexplained. Additional mechanistic and population-based studies are needed to explore 
whether an acquired or inherited disorder of folate metabolism plays a role in the etiology of 
clefts. The analysis of nutrient-related biomarkers and the evaluation of interactions with 
candidate gene polymorphisms and lifestyle and behavioral factors will be important in 
future studies of clefts.
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Figure 1. 
Mean maternal plasma folate concentrations of Utah oral cleft case (n=347) and control 
(n=468) mothers by interval between index birth and collection of maternal blood sample
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